ABSTRACT
Due to their anti-inflammatory and antioxidant properties, pentoxifylline and melatonin have been considered by many authors as potential adjuvants in coronavirus disease infection. The present study describes the development of a high performance liquid chromatography method with ultraviolet detection for the simultaneous determination of pentoxifylline and melatonin in spiked plasma samples. The chromatographic separation was performed isocratically at a temperature of 25 degrees, using a LiChrosorb (R) reverse phase-18 (125x4.0 mm, 5 mu m) as stationary phase. The mobile phase consists of water and acetonitrile in a ratio of 80:20 v/v. Under optimal chromatographic conditions, for both pentoxifylline and melatonin, the number of theoretical plates was >2000, peak asymmetry was <1.3 and resolution factors were >2. The relative standard deviations for pentoxifylline and melatonin for both intra-day and interday not exceeded 4 % and recoveries were in the ranges 99.46 %-102.51 % for pentoxifylline and 96.02 %-102.85 % for melatonin.
ABSTRACT
An accurate, easy, detailed, selective and fast RP-HPLC stability representative technique was developed and validated for assessment of ivermectin in tablet dosage form. The Reverse Phase High Performance Liquid Chromatographic technique was developed for routine quantification of ivermectin in laboratory prepared mixtures as well as in combined dosage forms. The chromatographic separation was accomplished with INERTSIL C-18 ODS 250x4.6mm, 5 mu m particle size column along with acetonitrile and methanol as the mobile phase at a flow rate of 1 ml/min. Quantification was completed by using a UV detector at 245 nm and the run time was 10 minutes. The retention time was found to be 4.198 min for ivermectin. The linearity was observed in the range of 1-32 mu g/ml with correlation coefficient r= 0.9798. The % RSD for intraday and interday precision was 1.352 and 1.589 respectively. The LOD and LOQ values were found to be 2.93 and 8.79, respectively. The system suitability parameters for ivermectin such as theoretical plates and tailing factor were found to be 129.949 and 2.0, respectively. Robustness was also studied and there was no significant variation in the system suitability of the analytical method by incorporating small changes in experimental parameters. The technique has been validated for linearity, precision, accuracy and other parameters as approved by ICH guidelines. The results obtained by RP- HPLC methods are found to be fast, detailed, selective and accurate. Therefore, proposed analytical method can be used for regular analysis of ivermectin in injection, tablet and other formulations.
ABSTRACT
4-Aminoquinoline including Hydroxychloroquine (HCQ), amodiaquine (AQ), Chloroquine (CQ) are a quinoline with an amino group at the 4th position with a basic side chain. They are generally used as antimalarial medications. HCQ and CQ are recommended by the World Health Organization on march 2020 the use as a possible treatment to coronavirus (COVID-19). Long-term of 4-aminoquinoline drugs administration can be associated with toxic side-effects on the outer retina and the retinal pigment epithelium. Therefore, their determination in biological samples is important. Several methods have been used for 4-Aminoquinoline compounds analysis, such as spectrophotometry, immunological, electrophoresis, chromatography and electroanalytical methods. Electrochemical methods are more preferable because they are simple, quick analysis and more sensitive performance. Up to now, numerous electrochemical methods have been used to detect those drugs. Nevertheless, the utilization of later techniques is limited. Therefore, this review describes different electrochemical sensors, which are used for 4-aminoquinoline electroanalysis in complex matrices such as pharmaceuticals and biological fluids. For this, the fundamental analytical performance of the chosen sensors is investigated. The selectivity and oxidation mechanisms for 4-aminoquinoline reported in the literature were discussed. Also, the application of these sensors for 4-aminoquinoline monitoring in biological and environmental samples is reported.
ABSTRACT
Corona virus disease 2019 (COVID-19) has posed a mounting threat to public health with worldwide outbreak caused by a novel virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recently, remdesivir (RDV) has been approved by Food and Drug Administration (FDA) for treating COVID-19 patients ≥12 years old requiring hospitalization. To the best of our knowledge, a simple method to estimate RDV in the pharmaceutical formulations using high-performance liquid chromatography (HPLC) is still unexplored, highlighting the need for a precise analytical method for its quantification. The prime purpose of the current investigation was to develop and validate a well-grounded HPLC method for quantification of RDV in pharmaceutical formulations. The best chromatogram was obtained by means of an Inertsil ODS-3V column using a mobile phase of milli-Q water modified to pH 3.0 with o-phosphoric acid and acetonitrile (50:50, % v/v) at a flow rate of 1.2 mL/min and wavelength of detector set at 246 nm with retention time being achieved at 6.0 min. The method was validated following International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2 (R1) guidelines for various parameters such as specificity and selectivity, system suitability, linearity, precision, accuracy, limits of detection and quantification, and robustness. The method developed for the quantification of RDV was found to be linear in the concentration range of 25-2,500 ng/mL with limit of detection and limit of quantification of 1.95 and 6.49 ng/mL, respectively. Assay value of 102% ± 1% was achieved for marketed injectable dosage form when estimated by the validated method. Therefore, in this study a simple, rapid, sensitive, selective, accurate, precise, and robust analytical method was developed and validated for the quantification of RDV using HPLC. The established method was successfully employed for quantification of RDV in marketed pharmaceutical formulation.